Other Information
−Removed: In September 2020, the Company’s Board approved our non-employee director compensation policy, a copy of which is filed herewith as Exhibit 10.2.
Exhibit Index
+Added: Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Form 8-K, filed on February 25, 2021)
Amendment No.
−Removed: 4 to the Second Restated License Agreement, by and among Altimmune, Inc.
−Removed: and Janssen Vaccines & Prevention B.V., dated as of July 28, 2020
−Removed: Non-Employee Director Compensation Policy
+Added: 6 to the Second Restated License Agreement, effective as of January 22, 2021, between Janssen Vaccines & Prevention B.V.
+Added: (formerly Crucell Holland B.V.) and Altimmune, Inc.
+Added: Statement of Work, dated March 9, 2021, by and between Altimmune, Inc.
+Added: and Lonza Houston Inc.
Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
10 unchanged sentences
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
+Added: Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.
ALTIMMUNE, INC.
−Removed: November 9, 2020
President and Chief Executive Officer (Principal Executive Officer)
−Removed: November 9, 2020
/s/ Will Brown
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.